VXL.V - Vaxil Bio Ltd.

TSXV - TSXV Delayed Price. Currency in CAD
0.2050
+0.0100 (+5.13%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1950
Open0.1950
Bid0.2000 x 0
Ask0.2050 x 0
Day's Range0.1900 - 0.2350
52 Week Range0.0250 - 0.3350
Volume7,078,838
Avg. Volume3,082,871
Market Cap18.231M
Beta (5Y Monthly)-6.55
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT

    NESS-ZIONA, Israel, March 27, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide a update of its COVID-19 research program and other updates. In February 2020 we announced that we believed that we had successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”).

  • GlobeNewswire

    VAXIL CHANGES WEBSITE DOMAIN NAME, PROVIDES UPDATE ON THE EXERCISE OF WARRANTS AND RECEIVES FINAL TSXV EXCHANGE APPROVAL ON THE DEBENTURE FINANCINGS

    NESS-ZIONA, ISRAEL, March 18, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has moved its website to a new domain – www.vaxil-bio.com. The Company is in the process of updating the website with specific information about our COVID-19 research program with respect of the potential vaccine. The Company also announces that since our recent press release dated March 15, 2020, a further, $70,000 (“Warrant Proceeds”) has been received from the exercise of 700,000 previously issued (January 2018) warrants, having an exercise price of $0.10 per warrant.

  • GlobeNewswire

    Vaxil Provides Update Website, Lab Work and the Exercise of Warrants

    NESS-ZIONA, Israel, March 16, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has experienced technical issues with its website and is working to restore access to it in the coming days. The Company also announces that since our recent press release dated March 10, 2020, a further, $354,000 (“Warrant Proceeds”) has been received from the exercise of 3,540,000 warrants, having an exercise price of $0.10 per warrant, that were previously issued in January 2018.

  • Baystreet

    Vaxil, Arbor at 52-Week Highs

    Vaxil Bio Ltd. (V.VXL) hit a new 52-week high of 30 cents Friay. No news announcements today Arbor ...

  • Baystreet

    Vaxil, WestBond at 52-Week Highs

    Vaxil Bio Ltd. (V.VXL) hit a new 52-week high of 27 cents Thursday. No news announcements today WestBond ...

  • GlobeNewswire

    VAXIL APPLIES FOR CORONAVIRUS VACCINE PATENT UNDER ITS ANTI-INFECTIVE VACCINES PLATFORM AND PROVIDES UPDATE ON THE EXERCISE OF WARRANTS

    NESS-ZIONA, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has submitted a new patent application for its anti-infective vaccines platform as a result of our recently announced COVID19 candidate discovery. Vaxil has applied for a US patent (U.S 62/987,310) on a coronavirus vaccine that is intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing an infectious disease as well as methods for producing a peptide vaccine against coronaviruses.

  • GlobeNewswire

    Vaxil Announces Closing of Bridge Financing and Provides Update on Corona Virus Vaccine Work

    NESS-ZIONA, Israel, March 04, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that, subject to receipt of final TSX Venture Exchange (“Exchange”) approval, it has closed on $36,000 (“Convertible Debenture Proceeds”) of convertible debentures from third parties (see press release of February 21, 2020) and $95,000 (“Debenture Proceeds”) of non-convertible debentures to certain insiders (“Debentures”). The Debentures bear an annual interest rate of 10% (“Debenture Interest”).

  • GlobeNewswire

    Vaxil Announces Financing Update

    NESS-ZIONA, Israel, Feb. 21, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, announces that further to its press release from January 28, 2020 in connection with the Company’s convertible debt financing (the “Initial Press Release”), and following the press releases from February 13, 2020 and February 18, 2020 (the “Recent Press Releases”) regarding the possible identification of a Corona Virus Vaccine, the Company will continue to pursue its convertible debt financing but with the following amended terms (the “Amendments”). The Company will be issuing convertible debentures (the “Offering”) with a face value of $1,000 (“Principal”) and bearing an annual interest rate (“Interest”) of 10% (“Convertible Debentures”) for gross proceeds of up to $200,000 (“Proceeds”).

  • CNW Group

    IIROC Trading Resumption - VXL

    IIROC Trading Resumption - VXL

  • GlobeNewswire

    Vaxil Provides Clarification and Further Information on the Possible Identification of a Corona Virus Vaccine

    NESS-ZIONA, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide further update to the Company’s press release dated February 13, 2020 on the possible identification of a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform.

  • CNW Group

    IIROC Trading Halt - VXL

    VANCOUVER , Feb. 14, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Vaxil Bio Ltd. TSX-Venture Symbol: VXL (All Issues) Reason: Pending Company Contact Halt Time (ET): 9:43 AM IIROC ...

  • GlobeNewswire

    Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing

    NESS-ZIONA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has completed in silico analyses and believes that it has successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform.

  • GlobeNewswire

    Vaxil Announces Private Placement Extension

    NESS-ZIONA, Israel, Nov. 26, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, is pleased to announce that the closing date for the previously announced non-brokered private placement of up to 18,750,000 common shares at a price of CDN$0.04 per share for gross proceeds of up to CDN$750,000 (the “Offering”) has been extended and is expected to close on or about December 27, 2019. The Offering is directed to all existing shareholders (including directors, officers and other insiders of the Company) as well as other Canadian and international investors. Closing of the Offering, which is at the discretion of the Company is subject to certain conditions including receipt of all necessary regulatory approvals, including approval of the TSX Venture Exchange.

  • GlobeNewswire

    Vaxil’s Annual and Special General Meeting

    VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), announces that at the Company's Annual and Special General Meeting, held on November 4, 2019 in Toronto, all resolutions were duly passed by shareholders. Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases.

  • GlobeNewswire

    Vaxil Announces Private Placement

    NESS-ZIONA, Israel, Sept. 10, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, is pleased to announce that the Company intends to complete a non-brokered private placement of up to 25,000,000 common shares at a price of CDN$0.04 per share for gross proceeds of up to CDN$750,000 (the “Offering”). The Offering is directed to all existing shareholders (including directors, officers and other insiders of the Company) as well as other Canadian and international investors. Closing of the Offering, which is at the discretion of the Company, is expected to be on or about September 30, 2019 and is subject to certain conditions including receipt of all necessary regulatory approvals, including approval of the TSX Venture Exchange.

  • GlobeNewswire

    Vaxil Appoints New Chairman

    NESS-ZIONA, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, is pleased to announce that it has appointed Mr. David Goren, the Company’s Chief Executive Officer as its Chairman, replacing Mr. Isaac Maresky, who continues to serve on the Company’s board of directors. Mr. Goren stated: "I am very excited about this appointment as the Company moves into this next exciting phase.

  • GlobeNewswire

    Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel

    NESS-ZIONA, Israel, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Vaxil Bio Ltd (TSX VENTURE: VXL), a biotech company focusing on innovative immunotherapy treatments for cancer and infectious diseases, announced today that it has entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of Ben-Gurion University (BGU) of the Negev. Vaxil has found great interest in the P-Esbp polymer-based macromolecule invented by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology, Prof. Gonen Ashkenazy of the Department of Chemistry and their joint PhD student Yosi Shamay all from BGU.

  • GlobeNewswire

    Vaxil Granted Significant US Patent for Anti-Infective Vaccines

    NESS-ZIONA, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotech focused on innovative immunotherapy treatments for cancer and infectious diseases, is pleased to announce that it has successfully obtained an additional U.S. Patent for anti-infective vaccines platforms. Vaxil has been granted U.S. Patent # 10,245,309 entitled “Antigen specific multi- epitope-based anti-infective vaccines.” This patent provides broad protection for treating pathogenic infections using vaccines based on a pathogen’s signal peptides, or T-cell populations enriched using these peptides. David Goren, Vaxil’s Chief Executive Officer commented: “We are very excited about this new patent as it provides further validation of the uniqueness of our innovative platform and encourages us to proceed with our research agenda, specifically in infectious disease.